RT Journal Article
SR Electronic
T1 Cyclin-dependent kinase 2 (Cdk2) controls phosphatase-regulated signaling and function in platelets
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.05.31.126953
DO 10.1101/2020.05.31.126953
A1 Paul R. Woods, Jr.
A1 Brian L. Hood
A1 Sruti Shiva
A1 Thomas P. Conrads
A1 Sarah Suchko
A1 Richard Steinman
YR 2020
UL http://biorxiv.org/content/early/2020/06/28/2020.05.31.126953.abstract
AB Cell cycle regulatory molecules including cyclin-dependent kinases can be recruited into non-nuclear pathways to coordinate cell cycling with the energetic state of the cell or with functions such as motility. Little is known about the role of cell cycle regulators in anucleate cells such as platelets. We report that cyclin-dependent kinase (cdk2) is robustly expressed in human platelets, is activated by thrombin and is required for platelet activation. Cdk2 activation required Src signaling downstream of the platelet thrombin receptor PAR1. Kinase-active cdk2 promoted the activation of downstream platelet kinases by phosphorylating and inactivating the catalytic subunit of protein phosphatase 1 (PP1). Erk was bound to PP1 in a complex with the PP1 regulator PPP1R12a (MYPT1) in platelets, and cdk2 inhibited the phosphatase activity of PP1 and PPP1R12a bound complexes. The requirement for cdk2 in Erk activation could be replaced by the phosphatase inhibitor calyculin if cdk2 was inhibited. Blockade of cdk2 kinase with chemical and peptide cdk2 inhibitors resulted in suppression of thrombin-induced platelet aggregation, and partially inhibited GPIIb/IIIa integrin activation as well as platelet secretion of P-Selectin and ATP. Together, these data indicate a requirement for cdk2 in platelet activation.Competing Interest StatementThe authors have declared no competing interest.